Suprefact 1 mg/ml solución inyectable 5,5ml 2st
Disponible à partir de 31-12-2029
Suprefact 1 mg/ml solución inyectable 5,5ml 2st
Treatment of advanced hormone-dependent prostatic carcinoma; however, it is not applicable after bilateral orchiectomy (since no further reduction in prostate levels would be obtained).
In women, pituitary desensitization in preparation for ovulation induction, administered in association with gonadotropins
Each ml of solution for injection contains 1.05 mg buserelin acetate, equivalent to 1 mg buserelin.
Each 5.5 ml vial of solution for injection contains 5.5 mg buserelin.
Excipient(s) with known effect
Each ml of solution for injection contains 10 mg benzyl alcohol and 2.255 mg (0.0980 mmoles) sodium.
Each 5.5 ml vial contains 55 mg benzyl alcohol and 12.4025 mg (0.5392 mmoles) sodium.